(Q37972768)

26 August 2017

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow (English)

1 reference

26 August 2017

1 reference

1 reference

1 reference

2

Patrick Marcellin

1 reference

26 August 2017

Tarik Asselah

1

1 reference

26 August 2017

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

32 Suppl 1

1 reference

26 August 2017

88-102

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Structure of the hepatitis C virus RNA helicase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Gene expression and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02699.X

10.1111/J.1478-3231.2011.02699.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22212578